New Drug Reviews

Revefenacin (Yupelri) for the Treatment of Chronic Obstructive Pulmonary Disease


Am Fam Physician. 2020 Jan 15;101(2):121-122.

Revefenacin (Yupelri) is a once-daily, nebulized, long-acting muscarinic antagonist labeled for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD).


Revefenacin is generally safe with minimal systemic adverse effects.1 As with other long-acting treatments, revefenacin should not be used to treat acute symptoms. Similar to other inhaled therapies, it has a theoretic risk of immediate hypersensitivity reaction and acute bronchospasm. Revefenacin is anticholinergic and may induce narrow-angle glaucoma or worsen urinary retention. Revefenacin has not been studied in pregnant women or breastfed infants. The manufacturer recommends against its use in patients with hepatic impairment or those taking rifampin or cyclosporine (Sandimmune).

 Enlarge     Print

DrugDosageDose formCost*

Revefenacin (Yupelri)

175 mcg once daily

175 mcg per 3 mL aqueous solution via nebulizer


*—Estimated retail price for one month of treatment based on information obtained at (accessed November 22, 2019).

DrugDosageDose formCost*

Revefenacin (Yupelri)

175 mcg once daily

175 mcg per 3 mL aqueous solution via nebulizer


*—Estimated retail price for one month of treatment based on information obtained at (accessed November 22, 2019).


Revefenacin was shown to be well tolerated in clinical trials. In two 12-week placebo-controlled trials of 1,225 patients with moderate to severe COPD, adverse effects leading to discontinuation were more common in patients receiving placebo (19%) than revefenacin (13%).2


Revefenacin is superior to placebo in improving forced expiratory volume in one second (FEV1) for patients with moderate to severe COPD. A 28-day randomized, double-blind study compared placebo and revefenacin in 355 patients with COPD, a mean age of 62 years, and a mean FEV1 of 44% of predicted. Patients were allowed to use inhaled corticosteroids and short-acting bronchodilators.3 Revefenacin improved FEV1 by at least 100 mL from baseline with effects lasting four hours or more; participants' mean number of albuterol puffs also decreased from three to two per day when using revefenacin. These results were replicated in an 85-day randomized, double-blind study (619 patients older than 40 years) in which participants were also allowed to use long-acting muscarinic antagonists and inhaled steroid therapy.4 This study demonstrated improvements in FEV1 that were sustained over the entire study period, but revefenacin has not been evaluated for its effect in decreasing exacerbations, hospitalization rates, mortality, functional status, and quality of life.


Revefenacin costs approximately $1,000 per month, compared with about $415 per month for common inhaled long-acting muscarinic antagonists such as tiotropium (Spiriva). This cost is more than that of most commonly used COPD medications. Revefenacin may require prior authorization or formulary exemption to obtain insurance coverage.


Revefenacin is administered as a nebulized solution once daily over eight minutes. The daily dosage is 175 mcg. Patients should be instructed on how to use the accompanying nebulizer. The sterile solution is provided in individual vials.

Bottom Line

Revefenacin is a once-daily nebulized alternative to metered dose long-acting muscarinic antagonists for patients with moderate to severe COPD. Given its expense, complicated administration process, and lack of evidence that it improves key patient-oriented outcomes, its use should be limited to patients who are unable to use a metered dose inhaler.

Author disclosure: No relevant financial affiliations.

Address correspondence to Joanne Wilkinson, MD, MSc, at Reprints are not available from the authors.


show all references

1. DailyMed. Drug label information. Yupelri —revefenacin solution. Accessed May 16, 2019.

2. Ferguson G, Pudi KK, Feldmann G, et al. Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD. Eur Respir J. 2017;50(suppl 61):1812.

3. Pudi KK, Barnes CN, Moran EJ, et al. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017;18(1):182.

4. Ferguson GT, Feldman G, Pudi KK, et al. Improvements in lung function with nebulized revefenacin in the treatment of patients with moderate to very severe COPD: results from two replicate phase III clinical trials. Chronic Obstr Pulm Dis. 2019;6(2):154–165.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, MMedEd, assistant medical editor.

A collection of STEPS published in AFP is available at



Copyright © 2020 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

More in AFP

More in Pubmed


Jan 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article